Regeneron Pharmaceuticals News - REGN

Sanofi SA and Regeneron Pharmaceuticals Inc. said it had positive results for an advanced trial of a treatment for patients with a chronic, allergic inflammatory disease of the esophagus.

The Phase 3 trial of Dupixent met both its co-primary endpoints, as well as important secondary endpoints, the companies said. The trial had 81 patients, ages 12 years and older, who had eosinophilic esophagitis.

The patients were able to show clinical and anatomic improvements, including the ability to swallow. Patients saw a 69% reduction in disease symptoms, as well as a 60% reduction in their esophageal eosinophilic count to a normal range, the companies said.

Eosinophilic esophagitis damages the esophagus and impairs its functions, making it difficult to swallow. It could also damage and scar the esophagus without treatment.

This was the first and only biologic to show "positive and clinically meaningful results" in an advanced trial, the companies said.